🔎 Trials Near Me

Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma › California

Pag-aaral pangklinika para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma sa California

5 pag-aaral para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ang naghahanap ng mga kalahok sa mga site sa California.

Mga Lungsod sa California

Opisyal na teksto ng pag-aaral (English)

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  • City of Hope, Duarte
  • Children's Hospital Los Angeles, Los Angeles
Nagre-recruitPhase 2
6 Months · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06514794

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

  • Loma Linda University Children's Hospital, Loma Linda
  • University of California, Los Angeles
  • University of California, San Francisco
Nagre-recruitPhase 1
Hanggang edad 39 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04972942

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Rady Children's Hospital, San Diego
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06390319

A Registry for People With T-cell Lymphoma

  • City of Hope Cancer Center (Data collection only), Duarte
  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
  • University of California San Francisco (Data collection only), San Francisco
  • at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

  • City of Hope, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2025 · NCT06462365

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.